TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25700774

Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed (DL1: 1250 mg/500 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed (DL0: 1250 mg/400 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed (DL2: 1500 mg/500 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed
Number of subjects: 18
Study: 25700777

Group type: EXPERIMENTAL
Intervention: CTC count (CellSearch®)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low serum albumin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Poor performance status
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ≥5 CTC/7.5 ml
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Triple negative subtype
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Composite criteria (<5 CTC/7.5 ml or relative decrease ≥-70% of the baseline CTC count)
Number of subjects: 56
Study: 25700893

Group type: COMPARATOR
Intervention: Water
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1% milk
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Regular cola
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet cola
Number of subjects: 29
Study: 25701004

Group type: EXPERIMENTAL
Intervention: Exercise training (ExTr) for 2 months
Number of subjects: 23
Study: 25701298

Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (PAPBI) - 40 Gray in 10 fractions over 2 weeks
Number of subjects: 70
Study: 25701314

Group type: EXPERIMENTAL
Intervention: DTaP-HBV-IPV/Hib combination vaccine
Number of subjects: 201
Study: 25701453

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarabazine) followed by EB (escalated BEACOPP) for PET-2-positive patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarabazine) for PET-2-negative patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EB (escalated BEACOPP) for PET-2-positive patients
Number of subjects: 50
Study: 25702731

Group type: EXPERIMENTAL
Intervention: Forced tobacco abstinence during incarceration
Number of subjects: 262
Study: 25703885

Group type: EXPERIMENTAL
Intervention: DAPT nonadherence before 6 months
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: DAPT nonadherence after 6 months
Number of subjects: 2265

Group type: COMPARATOR
Intervention: Major bleeding
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: DAPT nonadherence within 6 months
Number of subjects: 2265
Study: 25704212

Group type: COMPARATOR
Intervention: Pattern II subjects during arm lowering
Number of subjects: 82

Group type: COMPARATOR
Intervention: Mixed pattern I and II subjects during arm lowering
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pattern I subjects during arm lowering
Number of subjects: 82
Study: 25704439

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered intravenously every 2 weeks until progression or unacceptable toxic effects
Number of subjects: 117
Study: 25704448

Group type: EXPERIMENTAL
Intervention: Multiplex PCR targeting 15 viruses and four intracellular bacteria
Number of subjects: 254
Study: 25706232

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 50
Study: 25707037

Group type: EXPERIMENTAL
Intervention: Automessages encouraging group discussion on cessation-related topics and individualized autofeedback.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Automessages
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Specific tweet content (setting quit date, use of nicotine patches)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Countering roadblocks to quitting
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Expressions of confidence about quitting
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-evidence-based information about quitting
Number of subjects: 40
Study: 25708759

Group type: EXPERIMENTAL
Intervention: Attempted underwater en bloc resection (UEBR) using a 33-mm snare
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Attempted underwater en bloc resection (UEBR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy after UEBR
Number of subjects: 50
Study: 25709506

Group type: COMPARATOR
Intervention: Protocol A (standard protocol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocol B (GnRH antagonist initiated on day 10)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocol C (GnRH antagonist initiated on day 20)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocols B and C (GnRH antagonist protocols)
Number of subjects: 11
Study: 25710027

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Very low calorie diet
Number of subjects: 10
Study: 25710187

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis using [(123)I]FP-CIT SPECT images with support vector machines
Number of subjects: 654

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 654
Study: 25710456

Group type: EXPERIMENTAL
Intervention: Combination of panobinostat (30 mg) and carfilzomib (20/45 mg/m²)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of panobinostat and carfilzomib
Number of subjects: 44
Study: 25710539

Group type: EXPERIMENTAL
Intervention: 8-week multimodal physiotherapy programme (MPP) including land-based therapeutic exercise and adapted swimming
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 8-week multimodal physiotherapy programme (MPP)
Number of subjects: 175
Study: 25710659

Group type: EXPERIMENTAL
Intervention: Reversal of anticoagulation with INR <1.3 within 4 hours after admission
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Systolic BP <160 mm Hg at 4 hours
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Combination of INR reversal <1.3 within 4 hours and systolic BP <160 mm Hg at 4 hours
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: OAC resumption
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: OAC resumption in patients with atrial fibrillation
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Functional long-term outcome
Number of subjects: 1176
Study: 25710773

Group type: EXPERIMENTAL
Intervention: Sorbent Hemodialysis (Allient system; Renal Solutions, Warrendale, PA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Single-pass Hemodialysis
Number of subjects: 18
Study: 25710812

Group type: EXPERIMENTAL
Intervention: Gastric contractility modulation (GCM) device, laparoscopic implantation, n=8
Number of subjects: 16

Group type: COMPARATOR
Intervention: Insulin therapy, n=8
Number of subjects: 16
Study: 25710823

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 160

Group type: COMPARATOR
Intervention: WHO Growth Standards
Number of subjects: 160
Study: 25710916

Group type: EXPERIMENTAL
Intervention: Activation of the autonomous nervous system (ANS) measured through heart rate variability and skin conductance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real life situation (2 hours) and quiet environment (30 minutes) with stressful sound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interview to record feelings about events triggering anxiety
Number of subjects: 0
Study: 25711274

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Wall motion imaging
Number of subjects: 475
Study: 25711328

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests administered (QNPZ-8 score)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Geographical location
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Mild neurocognitive impairment (NCI) defined as z-scores < -1 in at least two of six cognitive domains
Number of subjects: 608
Study: 25711317

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25711640

Group type: EXPERIMENTAL
Intervention: African descent (AD) subjects
Number of subjects: 84

Group type: COMPARATOR
Intervention: European descent (ED) subjects
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both AD and ED participants
Number of subjects: 84
Study: 25712199

Group type: EXPERIMENTAL
Intervention: Monosegment ALPPS hepatectomy
Number of subjects: 12
Study: 25712310

Group type: EXPERIMENTAL
Intervention: TOOKAD(®) Soluble at 4 mg/kg
Number of subjects: 117
Study: 25712364

Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy for 14 days followed by telaprevir-based triple therapy after 4.3 to 5.7 years
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy
Number of subjects: 9
Study: 25712496

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (expiratory pressures ranged from 10 to 40 mm Hg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Breath holds ending on either inhalation or exhalation
Number of subjects: 9
Study: 25712687

Group type: EXPERIMENTAL
Intervention: BI-505 (0.09 mg/kg or higher doses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BI-505 (escalating doses from 0.0004 to 20 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BI-505 (10 mg/kg doses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BI-505 (various doses)
Number of subjects: 35
Study: 25713216

Group type: EXPERIMENTAL
Intervention: 3D (123)I-mIBG innervation maps
Number of subjects: 15
Study: 25713286

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25713293

Group type: EXPERIMENTAL
Intervention: ACEI/ARB therapy
Number of subjects: 0
Study: 25713436

Group type: EXPERIMENTAL
Intervention: T-DM1 (trastuzumab emtansine)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: T-DM1 plus radiotherapy
Number of subjects: 153
Study: 25713585

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel (Crinone 8% gel) + intercourse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaginal progesterone gel (Crinone 8% gel) + abstinence
Number of subjects: 20
Study: 25713599

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 25713600

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (initially in RCT phase)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg (initially in RCT phase)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 100
Study: 25713900

Group type: EXPERIMENTAL
Intervention: Urgent double-balloon endoscopy (DBE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Urgent video capsule endoscopy (VCE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both tests (DBE and VCE)
Number of subjects: 30
Study: 25714519

Group type: EXPERIMENTAL
Intervention: Early WMAs predictors
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Late WMAs predictors
Number of subjects: 301
Study: 25714828

Group type: EXPERIMENTAL
Intervention: Anticoagulants (vitamin K antagonists, factor Xa inhibitors, direct thrombin inhibitors)
Number of subjects: 17184

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 17184
Study: 25715311

Group type: EXPERIMENTAL
Intervention: Copper Bromide Laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple-Combination Cream
Number of subjects: 0
Study: 25715403

Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 575
Study: 25715872

Group type: EXPERIMENTAL
Intervention: Early mobilization during mechanical ventilation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Exercises in bed (N=94, 7%), standing at the bedside (N=11, 0.9%), walking (N=26, 2%)
Number of subjects: 192
Study: 25716221

Group type: EXPERIMENTAL
Intervention: Beta-blockers (bisoprolol for at least 48 hours)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Beta-blockers (chronic group)
Number of subjects: 48
Study: 25716544

Group type: EXPERIMENTAL
Intervention: DEBIO1143 (oral administration, doses from 5 to 900 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DEBIO1143 (oral administration, doses >80 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DEBIO1143 (oral administration)
Number of subjects: 31
Study: 25717286

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg twice daily or 15 mg twice daily for 3 weeks followed by 15 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: UFH/warfarin (activated partial thromboplastin time-adjusted intravenous unfractionated heparin followed by warfarin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 100

Group type: COMPARATOR
Intervention: UFH/warfarin
Number of subjects: 100
Study: 25719453

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 20/3 mg/kg twice-daily for 2 weeks, then adjusted to 25/3 mg/kg for patients <15 kg and 375/50 mg for patients 15 to <20 kg with an optimized background regimen (OBR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir with OBR
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 21
Study: 25719540

Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU)
Number of subjects: 15
Study: 25720077

Group type: EXPERIMENTAL
Intervention: Urinary Luteinising Hormone (LH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urinary Pregnanediol-3-glucuronide (P3G)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urinary Estrone-3-glucuronide (E3G)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Number of subjects: 40
Study: 25720673

Group type: EXPERIMENTAL
Intervention: HER2 status assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: HER2 status and overall survival (OS) analysis
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: HER2 mRNA expression
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: In vitro analysis of HER2 mutation V777L
Number of subjects: 213
Study: 25721307

Group type: EXPERIMENTAL
Intervention: AZD1152
Number of subjects: 0
Study: 25721728

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (485 STEMI patients without additional imaging)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Periprocedural complications
Number of subjects: 103
Study: 25721902

Group type: EXPERIMENTAL
Intervention: Fludarabine (F)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 227
Study: 25722272

Group type: EXPERIMENTAL
Intervention: Detection of serum anti-tissue transglutaminase antibodies during febrile illness
Number of subjects: 0
Study: 25722745

Group type: EXPERIMENTAL
Intervention: RNA-sequencing on the Illumina platform
Number of subjects: 3979
Study: 25723529

Group type: EXPERIMENTAL
Intervention: Altitude exposure at 1630 m
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Altitude exposure at 2590 m
Number of subjects: 51

Group type: COMPARATOR
Intervention: Altitude exposure at 490 m
Number of subjects: 51
Study: 25724984

Group type: EXPERIMENTAL
Intervention: Safe storage intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Legislative intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follow-up contact intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mobile phone contact intervention
Number of subjects: 0
Study: 25726315

Group type: EXPERIMENTAL
Intervention: LES electrical stimulation therapy (LES-EST) at 20 Hz, 215 μs, 3-8 mAmp, delivered over 30-minute sessions, 6-12 sessions per day, starting on day 1 after implantation.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LES electrical stimulation therapy (LES-EST)
Number of subjects: 25
Study: 25727057

Group type: EXPERIMENTAL
Intervention: Visual assessment from the side of the bed
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Visual assessment from the foot of the bed
Number of subjects: 125

Group type: COMPARATOR
Intervention: Visual assessment from the head of the bed
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Overall visual assessment
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Assessment of chest recoil from side and foot positions
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Assessment of CPR rate
Number of subjects: 125
Study: 25727117

Group type: EXPERIMENTAL
Intervention: Substance abuse programs
Number of subjects: 957

Group type: COMPARATOR
Intervention: Other sectors (primary care, mental health, social and community programs)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Clients without a substance abuse history
Number of subjects: 957
Study: 25727652

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Intraoperative lymphatic mapping (ILM)
Number of subjects: 139
Study: 25728316

Group type: EXPERIMENTAL
Intervention: Encepur(®) Children (conventional/accelerated conventional schedule)
Number of subjects: 4

Group type: COMPARATOR
Intervention: FSME-IMMUN(®) Junior (mixed series)
Number of subjects: 4
Study: 25728526

Group type: EXPERIMENTAL
Intervention: Alisertib (50 mg twice daily for 7 days in 21-day cycles)
Number of subjects: 249
Study: 25728732

Group type: EXPERIMENTAL
Intervention: Mild CKD (60-89 mL/min per 1.73 m²)
Number of subjects: 876
Study: 25728756

Group type: EXPERIMENTAL
Intervention: Reveal LINQ insertable cardiac monitor (ICM)
Number of subjects: 30
Study: 25730213

Group type: EXPERIMENTAL
Intervention: Vaginal bowel-control device
Number of subjects: 110
Study: 25730237

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with endometriosis
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain without endometriosis
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with myofascial trigger points
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with high anxiety
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain with high depression
Number of subjects: 49
Study: 25730284

Group type: EXPERIMENTAL
Intervention: Esophageal video capsule endoscopy (ECE)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Patient satisfaction (ECE)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Patient satisfaction (EGD)
Number of subjects: 330
Study: 25730509

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy with raltegravir and Truvada during primary HIV infection (PHI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Early antiretroviral therapy with raltegravir and Truvada during chronic HIV infection (CHI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both cohorts (PHI and CHI)
Number of subjects: 16
Study: 25731869

Group type: EXPERIMENTAL
Intervention: SSA/P-D
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Age and lesion size
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Adenomatous pit pattern
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Paris 0-Is component
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: HGD or cancer
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Age and Paris 0-Is component
Number of subjects: 207
Study: 25732635

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy based on ERCC1, RRM1, and TS protein expression
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-individualized treatment
Number of subjects: 128
Study: 25733005

Group type: EXPERIMENTAL
Intervention: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A) at maximum tolerated dose (MTD) of 59 mg/m².
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 (schedule B) at maximum tolerated dose (MTD) of 83 mg/m².
Number of subjects: 53
Study: 25733329

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour measured by accelerometer over 7 days, assessing total sedentary time and sedentary time in bouts ≥10 min.
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in bouts ≥10 min
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in bouts ≥10 min after adjusting for potential confounders
Number of subjects: 263
Study: 25733369

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 24 weeks (n = 55)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ledipasvir with or without GS-9669 or GS-9451 (n = 59)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Patients with HCV RNA ≥LLOQ at EOT
Number of subjects: 114
Study: 25733630

Group type: EXPERIMENTAL
Intervention: Afebrile malaria treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hookworm treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: S. haematobium treatment
Number of subjects: 41
Study: 25733641

Group type: EXPERIMENTAL
Intervention: Adherence to ACS cancer prevention guidelines (highest level)
Number of subjects: 476396
Study: 25734008

Group type: EXPERIMENTAL
Intervention: Early-transduced VSTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late-transduced VSTs
Number of subjects: 0
Study: 25734107

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) in TB patients
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) in non-TB patients
Number of subjects: 812

Group type: COMPARATOR
Intervention: Retention in care
Number of subjects: 812

Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 812

Group type: COMPARATOR
Intervention: Loss to follow-up
Number of subjects: 812